Washington University Presentations

Below are Washington University-affiliated presentations at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer, March 14-17 in Seattle. All times are Pacific.

Presentation details are subject to change. For the latest information, visit the meeting website.

 

Saturday, March 15

Presenter: Matthew Powell, MD
Presentation: Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced non-mutated epithelial ovarian cancer:  Results from the randomized phase 3 ENGOT-OV43/GOG-30
Session: Scientific Plenary III: Race for IMPACT: Late Breaking Abstracts
Time: 3:22 p.m.

 

Presenter: Yukihide Ota, MD, PhD
Presentation: RAD52 inhibition enhances olaparib efficacy in PARP inhibitor-resistant BRCA-deficient ovarian cancer
Session: Oral Featured Poster Session II: Multiple Ways to Make an IMPACT
Time: 4:17 p.m.

 

Sunday, March 16

Presenter: Joshua Brill, MD
Presentation: COPS5 depletion via CSN5i-3 downregulates DNA damage repair to synergize with Poly (ADP-Ribose) Polymerase inhibitors
Session: In-Person Poster Session
Time: 2:10-2:40 p.m.

 

Presenter: Rachel Furuya, MD
Presentation: Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial endometrioid adenocarcinoma (EEA)
Session: In-Person Poster Session
Time: 2:10-2:40 p.m.

 

Presenter: Deanna Wong, MD
Presentation: ALC1 Loss Expands the Therapeutic Utility of PARP Inhibitors in High Grade Serous Ovarian Cancer
Session: In-Person Poster Session
Time: 2:10-2:40 p.m.

 

Monday, March 17

Presenter: Lindsay Kuroki, MD
Presentation: Molecular classification and association with survival outcomes in high-intermediate and high-risk early stage endometrial cancers: Ancillary analysis of GOG-0249
Session: Focused Forum XIV: Molecular IMPACT
Time: 9:25 a.m.

 

Virtual

Presenter: Mark Valentine, MD, PhD
Presentation: Ineffective nonsense mediated decay is common in high grade serous ovarian cancer and may represent an unappreciated driver of tumor behavior
Session: Virtual Poster (available on event platform)